Flumazenil in Parkinson's disease
- Book ID
- 120849112
- Publisher
- Adis International Limited (now part of Wolters Kluwer Health)
- Year
- 2006
- Weight
- 133 KB
- Volume
- &NA;
- Category
- Article
- ISSN
- 1173-8324
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Manipulation of Ξ³βaminobutyrate (GABA) system has been little studied in Parkinson's disease, despite the fact that GABA subserves a large part of the basal ganglia, including the outflow tracts. To test whether antagonism of GABA could improve features of PD, we administered open label
Parkinsonβs disease is the second most prevalent neurodegenerative disease and is characterized by the irreversible loss of dopamine neurons. Despite its high prevalence in society and many decades of research, the origin of the pathogenesis and the molecular determinants involved in the disorder ha
Parkinsonβs disease is the second most prevalent neurodegenerative disease and is characterized by the irreversible loss of dopamine neurons. Despite its high prevalence in society and many decades of research, the origin of the pathogenesis and the molecular determinants involved in the disorder ha
## Abstract Flumazenil is a shortβacting intravenously administered Ξ³βaminobutyric acid (GABA) antagonist used to reverse the effects of benzodiazepines. Based upon current basal ganglion models in Parkinson's disease (PD), flumazenil could normalize neuronal signaling at several different location